Merck Expands PCSK9 Opportunity with Oral Option for PCSK9-Naive Patients in Q2 2026 Earnings

Oral PCSK9 vs injectable adoption: market opportunity and primary-care “democratization” dynamics (MRK’s LIPFENDRA)

1) Relative opportunity: why LIPFENDRA is framed as expansion vs “switching” from injectable PCSK9

Merck’s management explicitly downplays a “take share from injectable PCSK9” framing. They state they are “not focusing this market on how do we take share from the injectable PCSK9,” and justify that by pointing out that “injectables only reach about 5% or less of the total market.” ¹ They also contrast the number of people receiving lipid-lowering therapies versus those not meeting goals: they cite “30 million people receiving lipid-lowering therapies” in the U.S. but “who are not at their recommended LDL levels” and “who… even more [are] untreated.” ¹

Implication for your question (injectable switch vs PCSK9-naïve bulk): based on these remarks, Merck believes the larger addressable opportunity is broader under-treatment/goal-miss (i.e., PCSK9-naïve patients and non-optimized patients), with injectable PCSK9 representing a small penetration subset rather than the majority of demand. ¹

2) What “primary care adoption” likely depends on for an oral PCSK9

Merck highlights an adoption challenge tied to education and inertia—especially in primary care. They say they need to “translate” strong feedback from key scientific leaders into the primary care setting, and that “that will take some time,” but their “sales teams will be focused on ensuring the right education to the primary care setting as well as to patients on the importance of this medicine.” ² They also reference “inertia we’re working against,” while noting that guideline changes are intended to address it. ¹

So the adoption-dynamics thesis is: oral convenience may lower behavioral barriers, but commercial uptake in primary care still requires guideline-aligned education and overcoming inertia. ²¹

3) How oral PCSK9 could change “access” and adoption speed in practice

Merck describes the product launch/access work as actively designed for broad access. They say they “really tried to set this up for broad access in the way we priced it and the way we’re going.” ³ However, they temper expectations on speed: they believe it “is going to take time to get that access established,” so they “expect… the pace not be as fast out of the gate,” while still expecting “long term… definitely a blockbuster opportunity.” ³

3a) Payer/access channel: TRUMP/TumpRx (MFN-related channel) as a lever for primary-care reach

On your specific “availability” question, Merck gives a clear timeline direction around formulary/channel access. They say that under their MFN agreement they “commit[ted] to putting LIPFENDRA on TrumpRx,” that “those plans are underway,” and that “as soon as we get that going, we’ll get it on TrumpRx.” ⁴

This matters because primary-care usage is often constrained by managed-care formulary and pharmacy access dynamics; Merck is signaling that broadening access through that channel is a deliberate step, but not instantaneous. ⁴³

3b) Regulatory and guideline tailwinds intended to push earlier intervention

Merck points to updated U.S. dyslipidemia guidelines from the ACC/AHA that “reestablished and lowered LDL-cholesterol treatment goals,” including “to under 55 mg/dL for individuals with ASCVD who are at very high risk,” and emphasizes earlier intervention to reduce lifelong risk from prolonged elevated exposure. ⁵ Separately, they discuss guideline shifts for secondary ASCVD, stating the “vast majority” should be “less than 55,” consistent with Europe and other countries. ⁶

Interpretation for adoption: primary-care prescribing patterns typically respond to guideline thresholds; Merck appears to view these updates as a commercial “education” accelerator that complements the convenience benefit of an oral PCSK9. ⁶⁵

4) Injectable “switch” attractiveness vs the “PCSK9-naïve” market thesis: what Merck is implicitly signaling

Putting the remarks together:

• Injectables are a small penetrated slice (“5% or less”) of the total market reach. ¹
• Merck claims the unmet need is much larger than the current injectable-installed base because many are untreated or not at LDL goals despite lipid-lowering therapy. ¹
• The remaining lift is mainly adoption/education in primary care, not necessarily “conversion” from injectables. ²¹
• The oral form is intended to extend reach as the “first approved oral PCSK9 inhibitor” and a “convenient daily oral option.” ⁵⁷

Therefore, Merck’s stated commercial strategy implies that injectable PCSK9 switch exists as a dynamic, but it is not the core growth engine they want to rely on; the bigger engine is expanding treatment to the broader population that is currently outside recommended LDL targets—much of which may be PCSK9-naïve. ¹

5) Evidence of clinical/label confidence that can support primary-care adoption (demand creation)

Merck emphasizes the efficacy profile and label positioning. They say LIPFENDRA is shown to be “highly effective” with “up to a 60% reduction” in LDL “when added to a statin.” ⁵ They also describe a “clean label” and indicate “up to 60% LDL lowering,” which they believe “is going to be a meaningful treatment.” ³

While this is not a penetration statistic, it does matter for adoption because primary care often requires clear, easy-to-apply benefit framing (e.g., add-on to statins and LDL reduction). ³⁵

6) Practical “adoption pacing” expectations: why the first-year ramp may be gradual

Even with the oral advantage and guideline tailwinds, Merck expects slower initial adoption due to access establishment time and inertia:

• “Take time to get that access established” and “pace not be as fast out of the gate” ³
• They explicitly reference inertia they’re working against. ¹
• They position education efforts as necessary to translate scientific leader support into primary care. ²

Conclusion on democratization dynamics: Merck’s view is that oral PCSK9 can broaden accessibility and reach, but the primary-care uptake curve will likely be staged—first constrained by access/formulary/logistics (e.g., TrumpRx channel work), then accelerated as guideline-driven education and managed-care adoption catch up. ²⁴³¹

Bottom line answer (directly to your question)

• Switch vs naïve: Merck frames the largest opportunity as market expansion driven by under-treatment/goal-miss, noting injectables reach only ~5% or less of the total market, while there are tens of millions not at LDL goals or untreated despite lipid-lowering therapy. ¹
• Primary-care “democratization” adoption: They believe oral PCSK9 can help reach more patients, but adoption in primary care will require time for education and overcoming inertia, and it will also depend on access channels being fully established (including planned MFN-driven TrumpRx placement). ²¹⁴³
• Availability dynamics: They expect a slower initial pace “out of the gate” due to the time required to establish access, even while they remain confident in a long-term blockbuster outcome. ³

All of the above is consistent with Merck’s strategic emphasis on earlier, broader LDL intervention rather than relying primarily on replacing injectable PCSK9 usage among already-treated patients. ¹²